Title : Comparisons of the molnupiravir, sotrovimab, and remdesivir use for COVID-19 patients in a tertiary hospital of Japan
New antiviral agents for COVID-19, including molnupiravir for the oral treatment and sotrovimab as the monoclonal antibody for the intravenous treatment are currently authorized and available in addition to remdesivir for the intravenous treatment in Japan.
We investigate the clinical use of molnupiravir, sotrovimab, and remdesivir for COVID-19 patients in our tertiary hospital from January to May 2022, which was the omicron strains dominant term.
35 COVID-19 patients received the molnupiravir administration orally. Among the 35 patients, 32 patients were used combined with intravenous administration of sotrovimab. The patients were 67.3 years old (26-90 y.o) and all survived. In the same term, the patients treated by either sotrovimab alone or sotrovimab plus remdesivir were either 14 cases of 79.0 (63-92) y.o. or 26 cases of 59.3 (36-97) y.o., respectively. Furthermore, the mild/moderate patients treated by molnupiravir were 15/20 cases although all patients with sotrovimab alone were mild, and the patients treated by sotrovimab plus remdesivir were 19 mild and 7 moderate, respectively. All patients treated by sotrovimab plus remdesivir were survived similar to the patients treated by molnupiravir, however, one patient treated by sotrovimab alone was died.
Most of the molnupiravir were used in the combination with sotrovimab. Molnupiravir may be useful for the COVID-19 patients who could accept oral administration of antiviral agents in the clinical setting.